Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
Zheng Hu(Guangzhou Institutes of Biomedicine and Health), Guang‐Biao Zhou(Institute of Zoology)
Cited by 43
Related Papers
Cancerous inhibitor of PP2A is targeted by natural compound celastrol for degradation in non-small-cell lung cancer
|Carcinogenesis|2013|105
Skp1 in lung cancer: clinical significance and therapeutic efficacy of its small molecule inhibitors
|Oncotarget|2015|65